FILTER
LATEST INTERVIEWS
Barbara Weber
CEO, TANGO THERAPEUTICS
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Ángel Tobar
GENERAL MANAGER ANDEAN REGION, EPIROC
"Battery-charging technologies should be used in a similar way to cellphones, regardless of the brand"
Eduardo Denyer Angel
PRESIDENT, BRENNTAG LATIN AMERICA NORTH
Brenntag is growing rapidly in Mexico through aquistions and increasing market share and penetration.
Michael Bigham & Evan Loh
PARATEK PHARMACEUTICALS
Paratek focuses on drugs that target infectious disease and other difficult-to-treat conditions.
Fernando Gutiérrez
PRESIDENT, MEXICAN COLLEGE OF CIVIL ENGINEERS (CICM)
Mexico is upgrading its infrastructure, offering opportunities for steel producers and construction firms alike.
David Kelley
PRESIDENT AND CEO, CHAKANA COPPER
Chakana Copper recently listed on the TSX and is busy exploring its acquisition in Peru, the Soledad project.
Gorden Glenn
CHAIRMAN, PRESIDENT AND CEO, MINNOVA CORP.
Minnova explains to GBR how it is planning to speedily bring to production its PL gold mine in Manitoba.
Richard Pino
VICE PRESIDENT SALES AND MARKETING, LATIN AMERICA, CRODA DO BRASIL
Recent acquisitions and investments have considerably enlarged Croda's presence in Brazil both in manufacturing and in R&D with its new innovation center at Campinas.
Richard Peters
PRESIDENT AND CEO, MERRIMACK PHARMACEUTICALS
Merrimack Pharmaceuticals is focused on cancer treatment through a deeper understanding of cancer pathways and biological markers.
Ankit Mahadevia & Cristina Larkin
CEO & CHIEF COMMERCIAL OFFICER, SPERO THERAPEUTICS
Spero Therapeutics is developing new antimicrobial drugs to substitute those that have become ineffectual as they meeting resistance.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
